Sunday, October 29, 2017 9:00:01 AM
Just heard an NPR broadcast interviewing a sleep expert, who said evidence continues to support lack of sleep, inability to sleep well in middle age as a major cause of ensuing Alzheimer’s. Sound sleep induces waste protein (beta-amyloid, et al.) removal from nerves and neurons.
In relation to Anavex 2-73 (which wasn’t mentioned), the drug’s ability to induce strong, healthful sleep, before any Alzheimer’s symptoms begin, may be a major eventual use for the drug. Universal restoration or induction of good sleep in the Australian Alzheimer's patients in the Phase 1/2 study there is significant.
Here’s the scenario (mine). Anavex 2-73 gets approved to treat mid to mild level Alzheimer’s patients, a result of the big Phase 3 study soon to start. Better than anything on the market, it works for most, either stabilizing at-the-start cognition, or actually improves it.
Of course, families then will be bringing to their doctors older, or even middle-aged family members just starting to lose memory. Physicians recognize these behaviors as those seen at the start of Alzheimer’s, and, for the first time, they have a drug they can prescribe. So they start prescribing Anavex 2-73 at the earliest signs of the disease — with high rates of success.
And, with this, they find those people start to sleep well once again. They don't go on to dementia.
The correlation, connection, even cause of Alzheimer’s with early sleep lose or poor quality becomes well known. Finally (perhaps quickly), physicians then start prescribing the drug as a sleep loss prophylactic, knowing that chronic sleep loss or poor quality sleep is a strong predictor or cause of eventual Alzheimer’s. Get to it early, and results are better (perhaps 100%).
Finally, because it has virtually no side effects of concern, Anavex 2-73 becomes a drug prescribed, even mandated for all middle aged people. Health insurance companies quickly recognize that daily consumption of 50mg of Anavex 2-73 reduces the chances of Alzheimer’s by, say, 75%. Everyone in their health insurance plans is required to take the drug, before any symptoms appear.
Consequently, Alzheimer’s and Parkinson’s and Amyotrophic Lateral Sclerosis cases plummet. Health insurance rates are markedly reduced. People lead longer, more productive (health care insurance paying) lives. Medicare costs plummet. Everyone (except nursing homes) benefits.
Think this to be overly optimistic? Do your own look-up of “Alzheimer’s, poor sleep.”
Then, for now, just for fun, figure out a likely range of corporate revenues if every candidate American popped a Anavex 2-73 pill every day. Presently, there are about 40 million age 50 or older. Add in Europeans and others in developed countries around the world, and the number must approach or exceed 100 million. And for the foreseeable future, that number will grow each year.
Anavex 2-73 has the chance to be the best ever, all-win drug.
[This author advises that his postings should not be used to prompt any AVXL buy or sell decision. Anavex Life Sciences Corp is presently a small, no-revenues, no-product start up pharmaceutical. It may have a great future, as its science is unique and effective. But, of course, never put at risk any non-discretionary funds.]
Recent AVXL News
- Anavex Life Sciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference 2024 • GlobeNewswire Inc. • 09/03/2024 11:30:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/06/2024 09:21:05 PM
- Anavex Life Sciences Reports Fiscal 2024 Third Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 08/06/2024 11:30:00 AM
- Anavex Life Sciences to Announce Fiscal 2024 Third Quarter Financial Results on Tuesday, August 6, 2024 • GlobeNewswire Inc. • 08/01/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/30/2024 09:20:53 PM
- Anavex Life Sciences Announces Translational Biomarker Data for ANAVEX®2-73 (blarcamesine) in Fragile X Syndrome (Major Cause of Autism) at the 19th NFXF International Fragile X Conference • GlobeNewswire Inc. • 07/30/2024 11:30:00 AM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 07/29/2024 09:21:49 PM
- Results from Anavex Life Sciences Landmark Phase IIb/III Trial of Blarcamesine Presented at Alzheimer's Association Conference • GlobeNewswire Inc. • 07/28/2024 09:00:00 PM
- Anavex Life Sciences to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference • GlobeNewswire Inc. • 06/20/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/17/2024 11:30:10 AM
- Anavex Life Sciences Announces Expansion of Leadership Team • GlobeNewswire Inc. • 05/22/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/17/2024 10:01:00 AM
- Anavex Life Sciences to Present at the H.C. Wainwright 2nd BioConnect Investor Conference at NASDAQ • GlobeNewswire Inc. • 05/14/2024 11:30:00 AM
- Shareholders that lost money on Anavex Life Sciences Corporation(AVXL) Urged to Join Class Action - Contact The Gross Law Firm to Learn More • PR Newswire (US) • 05/10/2024 09:45:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:35:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 12:00:30 PM
- Anavex Life Sciences Reports Fiscal 2024 Second Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/09/2024 11:30:00 AM
- The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Anavex Life Sciences Corporation(AVXL) Shareholders • PR Newswire (US) • 05/07/2024 09:45:00 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/06/2024 10:03:33 AM
- Anavex Life Sciences Corporation Sued for Securities Law Violations - Contact The Gross Law Firm Before May 13, 2024 to Discuss Your Rights - AVXL • PR Newswire (US) • 05/03/2024 09:45:00 AM
- Anavex Life Sciences to Announce Fiscal 2024 Second Quarter Financial Results on Thursday, May 9th, 2024 • GlobeNewswire Inc. • 05/02/2024 11:30:00 AM
- May 13, 2024 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against AVXL • PR Newswire (US) • 04/26/2024 09:45:00 AM
- Contact The Gross Law Firm by May 13, 2024 Deadline to Join Class Action Against Anavex Life Sciences Corporation(AVXL) • PR Newswire (US) • 04/19/2024 09:45:00 AM
- The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 13, 2024 in Anavex Life Sciences Lawsuit - AVXL • PR Newswire (US) • 04/16/2024 09:45:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM